These data indicated that SAH-JGZ4 sensitized lung cancer cells to carboplatin or pemetrexed chemotherapy, which may rely on the comprehensive effects of not only promoting EGFR degradation but also blocking the compensation of oncogenic or bypass signals. The gene discussed is EGFR; the disease is lung carcinoma.